A multileft evaluation of the Biotest legionella urinary antigen EIA  by Harrison, Timothy et al.
ORIGINAL ARTICLE 
A multicenter evaluation of the Biotest legionella 
urinary antigen EIA 
Timothy Harrison', Ssren Uldum', Stella Alexiou-Daniel3, Jette Bangsbo~g~, 
Sverker Be~nander~,  Vladimir Drarar 6, Jerome Etienne 7, Jiiyen Helbig8, 
Diane Lindsay9, Ivo Lochman lo,  Teresa Marques11, Fernando de Ory 12, 
&or Tartak~vskii l~,  Giinther we walk^'^ and Franx Fehrenbach l 5  
'Respiratory and Systemic Infection Laboratory, Central Public Health Laboratory, London, UK; 
2Neisseria Department, Statens Serum Institut, Copenhagen, Denmark; 3Department of 
Microbiology, Aristolian University of Thessaloniki, Thessaloniki, Greece; 4Department of Clinical 
Microbiology, Rigshospitalet, Copenhagen, Denmark; 5Department of Clinical Microbiology, 
Karolinska Sjukhuset, Stockholm, Sweden; 6National Legionella Reference Laboratory, VySkov, 
Czech Republic; 'Centre National de Reference des Legionella, Lyon, France; 81nstitute of Medical 
Microbiology and Hygiene, University Hospital of Dresden, Dresden, Germany; 'Scottish Legionella 
Reference Laboratory, Stobhill Hospital, Glasgow, UK; 'oIlepartment of Immunology, Regional 
Institute of Hygiene, Ostrava, Czech Republic; l1  Microbiology Laboratory, Hospital Santa Cruz, 
Portugal; 12Servico de Microbiologia Diagnostica, Centro National de Microbiologia, Instituto de 
Salud Carlos 111, Majadahonda, Madrid, Spain; I3Gamaleya Institute, Moscow, Russia; 
14Bundesstaatliche bakteriologisch-serologische Untersuchungsanstalt, Vienna, Austria; 15Robert Koch 
Institute, Berlin, Germany 
Objectives: To undertake a multicenter study to  evaluate the Biotest legionella urinary antigen enzyme immunoassay 
(EIA) performance against those ElAs already in use in 14 European laboratories. 
Methods: Each laboratory examined urine specimens from appropriate patients using both their current assay and the 
Biotest EIA. Each examined: a standard panel of 12 coded urine samples (distributed by Biotest); a panel of 10 coded 
urine samples provided as part of a European external quality assurance (EQA) scheme; urine samples from patients 
with proven legionnaires' disease (LD); urine samples from patients with pneumonia of microbiologically proven cause 
other than LD; and urine samples submitted for routine examination. Thus, the performance of the Biotest assay (in 
comparison with current EIAs), its specificity and utility, and the inter-laboratory agreement were assessed. 
Results: Inter-laboratory agreement was excellent, with all participants obtaining the expected results for 20 of 22 
coded urine specimens. Specificity, determined using 123 specimens from patients with infections of known etiology, 
was 100%. The Biotest EIA gave positive results in 86% of specimens which had been positive in the laboratories' current 
EIAs, and in  94.6% of those specimens which were positive for Legionella pneumophila serogroup 1. 
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Conclusions: The Biotest EIA is simple to use and specific and the results obtained in different laboratories show 
excellent agreement. The assay compares well with existing EIAs, at least for L. pneumophila serogroup 1. 
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INTRODUCTION 
Estimated rates of Legionnaire’s disease (LD) in 
European countries averaged 4.45 cases per million of 
population in 1996, with a total of 1563 cases reported 
to the European Working Group on Legionella 
Infections (EWGLI) 111. However, studies in Europe 
and elsewhere indicate that this probably represents 
10% or less of actual cases [2,3]. This poor detection 
rate is due, at least in part, to the cumbersome diag- 
nostic techniques in routine use. Culture of legionellae 
from respiratory specimens is relatively slow (3-10 days) 
and possibly insensitive, and requires a high degree 
of expertise. Direct fluorescent antibody staining of 
respiratory specimens is rapid and there are excellent 
reagents commercially available, but the sensitivity of 
this technique is poor (25-70%) 141. The most widely 
used diagnostic method remains, therefore, estimation 
of serum antibody levels 141. Unfortunately, this 
approach does not often allow a diagnosis to be 
established during acute illness, and so has little value 
in patient management or in the early detection of 
outbreaks. 
In contrast, it is now well established that the use 
of enzyme immunoassays (EIAs) for the detection of 
Legionella pneumophila antigen in urine allows diagnoses 
of LD to be established early in the course of infection. 
Until recently, however, the use of such assays was 
restricted to those few reference laboratories able to 
develop and maintain in-house EIAs [5-71. 
The first widely available commercial assay for the 
detection of legionella urinary antigen was a radio- 
immunoassay (Du Pont Co., Wilmington, USA) but, 
although apparently sensitive and specific [8], this 
was not widely used, probably because of both cost 
and safety considerations. More recently, the first 
commercial EIA kit (Binax Legionella Urinary Antigen 
EIA, Binas, Portland, USA) was produced. This kit, 
which is reported to be sensitive and specific, is only 
intended for the detection of L. pneurnophila serogroup 
1 infections and is also considered to be expensive 
to use 191. Recently, a second commercial EIA has 
become available (Biotest Legionella Urin Antigen 
EIA, Biotest AG, Dreieich, Germany). In addition to 
L. przeuvnopkila serogroup 1 urinary antigen, this kit is 
intended to detect antigen from other L. pneumoplzila 
serogroups as well as other Legionella species. 
The study presented here had three aims: first, to 
evaluate the performance of this new assay against that 
of other EIAs currently in use, with particular reference 
to L. pneumophila serogroup 1, the commonest cause of 
legionellosis; second, to determine whether L. pneumo- 
phila nonserogroup 1 cases could be detected with 
confidence; and third, to investigate the comparability 
of results obtained in 14 European laboratories, each 
of which is a local or national legionella reference 
laboratory which contributes to the EWGLI surveil- 
lance scheme. 
MATERIALS AND METHODS 
EIA systems 
Ten laboratories used the Binax EIA kit (Binax, 
Portland, USA), according to the manufacturer’s 
instructions, as their ‘current assay’. A further four 
laboratories each used their own ‘in-house’ assay. 
Detailed methodologies and evaluation data for these 
EIAs have been published elsewhere [5,10-121. 
The Biotest EIA kit (Biotest AG, Dreieich, 
Germany) is a standard ‘sandwich’ ELISA which uses 
a polyclonal rabbit antiserum to capture soluble anti- 
gen and peroxidase-labeled rabbit antibodies to detect 
immobilized antigen. The kit was used by all parti- 
cipants according to the manufacturer’s instructions. 
To avoid any possible discrepancy in results of the 
two tests due to the effects of storage on specimens, all 
urine samples were examined for this study in parallel 
by both the Biotest EIA and the laboratories’ ‘current 
assay’. 
Inter-laboratory agreement 
This was determined using two panels of urine 
specimens which were coded and distributed ‘blind’ to 
each participating laboratory. Laboratories were asked 
to record the optical density (011) values obtained for 
each specimen, together with the calculated cut-off 
values for each batch of specimens tested. 
Panel I was prepared by Biotest AG, was dispatched 
frozen to participants, and comprised 12 urine samples 
obtained froin patients with culture-proven L. yneumo- 
phila infection (nine samples) or healthy donors (three 
samples). In some cases the urine samples had been 
diluted in ‘negative urine’ to achieve the desired antigen 
concentration. Thus two specimens were intended to 
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be strongly positive, five to be positive, two to be 
weakly positive and three to be negative. 
Panel I1 was prepared by the Respiratory and 
Systemic Infection Laboratory, Colindale from speci- 
Table 1 Estimate of the specificity of the Biotest EIA, 
compared with the ‘current assay’, determined using urine 
specimens from patients with lower respiratory tract 
infections of known etiology 
Number of samples 
positive using: 
Causative organism“ Biotest ‘Current assay’ 
Streptococcus pneumoniae 
Mycoplasma pneumoniae 
Chlamydia spp. 
Haemophillrr injuenzae 
Pseudomonas aeruginosa 
Moraxella catarrhalis 
Coxiella burnetii 
Mycobacterium tuberculosis 
Escherichia coli 
Respiratory syncytial virus 
Influenza A virus 
Candida albicans 
Plasmodium falciparum 
0/48 
0129 
0/13 
016 
0/2 
0/1 
0/1 
0/1 
0/1 
0/2 
0/1 
0/1 
(RSV) 0/17 
Totals 0/123 
0/48 
0/29 
0/13 
0/6 
0/2 
0/1 
0/1 
0/1 
0/1 
0/17 
0/2 
o/ 1 
011 
0/123 
‘Evidence for the etiology: S. pneumoniae-antigen in urine/and or 
cultured from blood (38), cultured from sputum (9), not stated (1); 
Mycoplasma pueumoniae-positive serology (28), two also P C R  
positive, one PCR positive only; Chlamydia spp.-serology (1 l), 
DFA (2); H. influenroe-culture from tracheal aspirate (3), from 
sputum (3); Pseudomonas aeruginosa-culture from tracheal aspirate 
(l), from sputum (1); Moraxella catarrhalis-culture fiom sputum; 
E. coli and Candida albicans-cultured fiom tracheal aspirate; Coxiella 
burnetii-serology; influenza A 4 i r e c t  fluorescent antibody (DFA) 
in nasopharyngeal aspirates (NPA) (I), serology (1); RSV-all DFA 
in NPAs; Mycobacterium tuberculosis-not stated; Plasmodium 
jalciparum-positive blood film in malaria case complicated by adult 
respiratory distress syndrome ( A R D S ) .  
mens submitted by participating laboratories. It was 
dispatched unfrozen to participating laboratories as 
part of the external quality assurance (EQA) scheme 
recently established by EWGLI laboratories. This panel 
comprised 10 urine samples. The intended results for 
these were: positive (four samples), equivocal (defined 
as an OD? 10% ofthe originatinglaboratory’s EIA cut- 
off value, two samples) and negative (four samples). 
Performance of the Biotest EIA-combined results from 
all participants 
Each participant selected and examined urine speci- 
mens from a variable number of patients either with 
evidence of legionella infection, or with evidence of 
infection due to another specific microorganism. The 
combined data were used to estimate the specificity and 
sensitivity as follows. Specificity was determined using 
single urine samples from 123 patients with pneumonia 
or lower respiratory tract infection of known etiology 
(Table 1). Performance was assessed against single urine 
samples from 189 patients with evidence of legionella 
infection (Tables 2 and 3). Urine samples from 143 
(76%) of these patients had been previously found to be 
positive in the ‘current assays’ (Table 2), and these were 
used to estimate the comparative sensitivity of the 
Biotest EIA. Urine samples from 46 of the patients, 
which had been previously found to be negative, were 
also included to determine whether the Biotest assay 
could detect antigen ‘missed’ by current assays (Table 3). 
To assess the utility of the Biotest kit in general use, 
unselected urine samples from 228 patients submitted 
for routine L. pneumophila antigen detection were 
examined in various laboratories using both the Biotest 
kit and their current assay. 
Table 2 Comparative performance of the Biotest EIA, estimated using urine specimens shown to be positive with the 
‘current assays’ obtained from patients with proven Legionella spp. infection 
Number of samples positive using: 
Evidence of etiology Biotest ‘Current assay’ 
Culture-proven L. pnelrmophila serogroup 1 47/49 49/49 
Four-fold rise in titer to L. pneumophila serogroup 1 
Total for L. pneumophila serogroup 1 88/93 (94.6%) 93/93 (100%) 
41/44 44/44 
Culture-proven L. pneumophila nonserogroup 1 
DFA (L. pneumophila) 
Four-fold rise in titer to L. pneumophila nonserogroup 1’ 
P C R  positive 
0 /8  
6/6 
2 / 3  
9/9 
818 
616 
313 
9/9 
‘Current assay’ positive with no other evidence 18/24 24/24 
Total for Legionella spp. 123/143 (86%) 143/143 (100%) 
~~~ ~~ ~ ~~ ~ 
’L.  pneumophila serogroup 2 (l), serogroup 3 (3) ,  serogroup 4 (l), serogroup 6 (2) ,  serogroup 10 (1) 
’L.  pneurnophila serogroup 3 (2), serogroup 6 (2). 
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Table 3 Ability of the Uiotest EIA to detect legionella urinary antigen in samples shown to be negative with the ‘current 
assays’ from patients with proven Legionella spp. infection 
Number of samples positive using: 
Evidence of etiology Biotest ‘Current assay’ 
Culture-proven L. pneurnophila serogroup 1 2/7 0/7 
Four-fold rise in titer to L. prierrmopkila serogroup 1 
DFA (L. pneumupkila) O/h O/h 
Culture-proven L. ptreumopkila nonserogroup 1 1/6 0 /6  
Four-fold rise in titer to L. pneirmopkila nonserogroup 1 
PCR positive o/ 1 011 
Totals 5/46 (11%) 0 / l h  (0%) 
2 / 2 0  0/20 
0/6 O/h 
A selection of  40 urine samples, including some 
from known positive and known negative patients, 
were examined with and without a 5-min boiling step 
before the EIA. 
RESULTS 
Inter-laboratory agreement 
Panel I 
Because of difficulties with the international postal 
authorities, one laboratory did not receive Panel I. T h e  
reported results for the remaining 13 participants were 
in complete agreement for all the samples using the 
Biotest kit. Reported results for the two weakly positive 
saniples (B3 and B4) were between the cut-off value 
and the cut-off ? 0.2 OD in the cases of three and two 
laboratories respectively. T h e  manufacturer’s instruc- 
tions recommend that such results are repeated to 
confirm the positive result. Results for the ‘current 
assay’ were very similar to those obtained with the 
Biotest kit, except in the cases of  B3 and B4, where 
two laboratories obtained negative results for both 
(Table 4). 
Panel I1 
All 14 participants reported complete agreement for 
the four positive and four negative samples using the 
Biotest EIA. For the two ‘equivocal’ specinlens (E3 and 
EX), both were found to be positive by 12 laboratories 
and negative by two. Again, results with current assays 
were very similar, except for E 3  and E8, where seven 
and five laboratories, respectively, found these to be  
negative (Table 4). 
Thus overall for 20 of 22 coded specimens the 
Biotest kit results were in  complete agreement among 
all laboratories. For 18 of  22 specimens, the results were 
in agreement for both the Biotest and current assays 
among all laboratories. T h e  four specimens which were 
intended to give weakly positive or  equivocal results 
were reported by most laboratories to be positive, but 
one laboratory found all to be negative in its current 
assay (Table 4). 
Performance of the Biotest EIA-combined results from 
all participants 
All 123 urine specimens from patients with non- 
legionella infections gave a negative result with both 
the Biotest and current assays (Table 2). Thus specificity 
is estimated to be 100% for this series of  patients. 
T h e  comparative performance of the Biotest EIA 
was estimated using single urine specimens from 143 
patients which had been previously shown to be 
positive in participants’ ‘current assays’. I t  was found 
that 123 (86%) of  these were also positive in the Biotest 
Table 4 Number of participating laboratories with positive and negative results for the four urine sainplet giving weakly 
positive (B3 and B4) or equivocal (E3 and E8) result5 
Urine saiiiplc 
13.3,’ Bl“ E3 EX 
Positive Negative Posirioe Negativc Pocirive Nrgativc Positive Negativc 
Biorest 13 0 13 ( I  12 2 12 - 3
Current acsays 1 1  2 1 1  - 7 7 9 3 7 
‘Only 13 laboratorles reported rezults with this panel 
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EIA (Table 3). Of  these 143 specimens, 93 were 
obtained from patients with proven (49) or likely 
(44) L. pneumophila serogroup 1 infection, and 88 
(94.6%) of these were positive by the Biotest EIA. 
Urine specimens previously found to be negative in 
participants’ ‘current assays’ were also available from 
46 patients with good microbiological evidence of 
legionella infection (Table 3). O f  these, five (11%) 
were found to be positive in the Biotest EIA. These 
comprised specimens from: two patients with culture- 
proven L. pneumophila serogroup 1 infection, a patient 
with culture-proven L. pneumophila serogroup 6 in- 
fection and two patients with serologic evidence of a 
L. pneumophila serogroup 1 infections. 
The Biotest kit was found to be simple to use and 
generally gave clearcut results. Of the 228 unselected 
urine samples examined, nine (4%) gave positive results 
in the Biotest EIA. One of these was not confirmed by 
the ‘current assay’. This was obtained from a patient in 
whom the diagnosis was subsequently confirmed by a 
four-fold rise in titer (against L. pneurnophila serogroup 
1) in paired sera together with a positive PCR result for 
a respiratory specimen. One sample was found to be 
positive using the ‘current assay’ but was Biotest 
negative. This was obtained from a patient who died 
shortly after admission to hospital, and no other 
specimens were available for examination. 
The 40 specimens examined with and without a 
boiling step prior to testing showed no obvious 
difference in the OD values obtained (data not shown); 
d l  positive results remained positive and all negative 
results remained negative. 
DISCUSSION 
LD is an uncommon form of pneumonia, probably 
accounting for less than 5% of all pneumonia cases 
requiring hospital admission [ 131. However, the 
diagnosis and detection of cases of LD is important 
for several reasons. First, although uncommon overall, 
legionella infections are much more significant in 
the context of severe community-acquired pneumonias, 
possibly being the second commonest form, accounting 
for 14-37% of cases, with an associated mortality rate 
in excess of 25% [14]. Second, the early recognition of 
cases of LD allows the source of actual, or potential, 
outbreaks to be identified and hastens the irnplemen- 
tation of appropriate control measures. As LD has no 
particular clinical features that clearly distinguish it 
from other pneumonias, laboratory investigations must 
be relied upon if a diagnosis is to be established with 
any confidence. 
The advantages of diagnosing LD by urinary 
antigen detection, such as early detection, rapidity of 
testing and the ease of specimen collection, were 
recognized soon after LD was first described [15,16]. 
However, until recently the widespread application of 
this method has been inhibited by the lack of reliable 
and widely available diagnostic reagents. 
The first commercially available EIA was the Binax 
kit. Although it has not been evaluated compre- 
hensively, studies using this assay have found it to be 
specific and to be reasonably sensitive [9,17]. Unfor- 
tunately, at  present, this kit is expensive, particularly 
where specimen throughput is low [9]. Obviously, the 
availability of other commercially produced kits is likely 
to lead to overall reductions in costs per test. However, 
it is clearly important that, in addition to being 
economic to use, any new kits also show good perfor- 
mance characteristics. By combining the resources of 
14 European laboratories active in the study of 
legionella infections, we were able to obtain sufficient 
material to make a rapid and valid assessment of the 
Biotest EIA. 
For an infection of low prevalence, such as LD, 
test specificity is of paramount importance. The data 
presented indicate that, at least for patients with lower 
respiratory tract infections, the specificity of the Biotest 
and ‘current assays’ is excellent, with no false-positive 
results being found among the 123 non-LD patients 
examined. Although not encountered in this study, it 
has been reported that some urine samples give false- 
positive results, due to non-specific reactions, which 
can be removed by boiling the sample prior to testing 
[5,18]. Although it is not a stated prerequisite in the 
manufacturer’s instructions, it is noted that boiling 
samples does not interfere with the Biotest assay. The 
limited data presented here confirm this claim, at  least 
for L. pneumophila serogroup 1, and indicate that if it is 
considered desirable, positive results can be Confirmed 
after boiling. 
As there is no reliable standard test for the diagnosis 
of LD and, in this study, the precise timing of specimen 
collection in relation to the appearance of symptoms 
was unknown, it was not possible to determine the 
diagnostic sensitivity of the Biotest EIA with any 
confidence. Rather, the performance was assessed in 
comparison with those assays already in use. However, 
patients with culture-proven, or a four-fold or greater 
rise in antibody titer against, L. pneumophila serogroup 
1 might be reasonably considered as confirmed cases of 
L. pneumophila serogroup 1 infection. Combination of 
the results for these patients in Tables 3 and 4 results 
in the overall sensitivity for the detection of L. 
pneunzophila serogroup 1 antigen being 76.7% (92/120) 
and 77.5% (93/120) for the Biotest and ‘current assay’ 
respectively. These values, which are very close, match 
well with other reports of the sensitivity for diagnosing 
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L. pneumophila serogroup 1 infection by detecting 
urinary antigen [5,8,12]. However, it is quite likely that 
they are underestimates of the real diagnostic sensitivity, 
as some samples might well have been collected after 
cessation of antigen excretion. Although 10 labora- 
tories used the Binax kit as their ‘current assay’, 64% of 
the specimens used in the estimation of sensitivity were 
contributed by the four laboratories that used in-house 
assays. Thus the sensitivities of these two commercial 
kits could not be meaningfully compared. 
Overall, in urine samples previously shown to be 
positive in current assays, the Biotest kit was positive in 
94.6% for L. pneumophila serogroup 1 infections and in 
86% for L. pneumophila of any serogroup. Evidence that 
the kit could detect L. pneurnophila nonserogroup 1 
infections was found, as positive results were obtained 
with urine samples from two patients with evidence 
of L. pneumophila serogroup 6 infection (one culture 
proven) and one with evidence of L. pneumophila 
serogroup 3 infection. However, none of the eight 
‘current-assay’-positive specimens from patients with 
culture-proven L. pneumophila nonserogroup 1 infection 
was positive with the Biotest kit (Table 2). Positive 
results for these latter specimens were obtained using 
either of two broadly reacting and sensitive in-house 
EIAs [12,19]. Whether or not the Biotest EIA’s failure 
to detect the antigen was due to the sensitivity (in terms 
of ability to detect very small quantities of antigen), 
compared with these assays, or due to the specificity of 
the assay (in terms of ability to detect a broad range of 
L. yneurnoplzila serogroups), is not clear. 
A large proportion of cases of LD are now 
recognized to be travel-associated, particularly in 
patients returning from holidays in other countries, and 
a sophisticated surveillance scheme has been developed 
to detect associated cases even though they may be 
widely dispersed within Europe [l]. The implication 
that a particular hotel or resort is the source of LD 
infections can have severe economic consequences. 
Hence, central to the EWGLI scheme are the reliability 
of the diagnostic tests used, and the uniformity with 
which diagnostic criteria are applied when defining 
cases. The data presented here show that, overall, the 
reproducibility of the EIAs both within and between 
laboratories was excellent, indicating that considerable 
confidence can be placed on the results obtained using 
them. Not surprisingly, the reproducibility for those 
specimens considered ‘equivocal’ showed some vari- 
ability and there is clearly an important role for EQA 
schemes to help ensure consistency of reporting. For 
international surveillance purposes, a positive urinary 
antigen result is currently considered as presumptive 
evidence of legionella infection rather than diagnostic 
[20]. In the light of earlier reports [21] and the findings 
reported here, it is clear that this classification should 
be reviewed. 
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